首个靶向β-淀粉样蛋白的阿尔茨海默病药物aducanumab  

Aducanumab,the first Alzheimer’s disease therapeutic drug targeting amyloid beta

作　　者：张芳[1] 刘杰[1] 孙韬华[2] 陈安进[2] 石杰[2] ZHANG Fang;LIU Jie;SUN Tao-hua;CHEN An-jin;SHI Jie(Department of Pharmacy,Qingdao Municipal Hospital,Qingdao 266011,China;Department of Drug Clinical Trials,Qingdao Municipal Hospital,Qingdao 266011,China)

机构地区：[1]青岛市市立医院药学部,青岛266011 [2]青岛市市立医院药物临床试验研究科,青岛266011

出　　处：《中国新药杂志》2022年第10期929-932,共4页Chinese Journal of New Drugs

基　　金：2020年山东省医学会治疗药物监测科研基金(YXH 2020ZX058)。

摘　　要：aducanumab是一种可定向清除蓄积的可溶和不可溶性β-淀粉样蛋白斑块的人源化单克隆抗体。大脑中β-淀粉样蛋白斑块蓄积是阿尔茨海默病的病理特征之一。2021年6月,aducanumab获得美国FDA加速批准上市,用于治疗阿尔茨海默病,本文对其作用机制、药理作用、药动学、临床研究等进行综述。Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. In June 2021,aducanumab received accelerated approval from the US FDA for the treatment of Alzheimer’s disease. This article reviewed the mechanism of action,pharmacological studies,pharmacokinetics and clinical studies of aducanumab.

关 键 词：aducanumab 阿尔茨海默病 Β-淀粉样蛋白 临床研究 

分 类 号：R971[医药卫生—药品]